2.9. Analysis.
Comparison 2 ICS versus placebo, parallel‐group studies, greater than 2 months to 6 months (all doses), Outcome 9 No. of patients with at least one exacerbation.
Comparison 2 ICS versus placebo, parallel‐group studies, greater than 2 months to 6 months (all doses), Outcome 9 No. of patients with at least one exacerbation.